In addition, Castelli et al. found that treatment of breast cancer stem cells with the specific PPARα antagonist GW6471 reduced cell proliferation, viability, and spheroid formation, resulting in metabolic dysfunction and apoptosis [107]. Here, PPARA is linked to breast cancer.